I 301
Alternative Names: I-301; TC-I301Latest Information Update: 10 Apr 2023
At a glance
- Originator TCRCure Biopharma
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Glioma
Most Recent Events
- 29 Mar 2023 Preclinical trials in Glioma in China (Parenteral) prior to March 2023 (TCRCure Biopharma website, March 2023)
- 29 Mar 2023 TCRCure Biopharma plans a phase I trial for Glioma (Second-line therapy or greater) (Parenteral) (TCRCure Biopharma website, March 2023)